RARA CRAFT DATABASE for FDA Medical Devices
510(k)K173576

FDA DEVICE FACTS

Pristina Serena

GE Healthcare

FDA-sourced product information for medical-device development research. Use the official FDA sources at the end of this page when the original public document wording is needed.医療機器開発の調査用に、FDA の公開情報から取った製品情報を示しています。公開文書の原文が必要なときは、このページの最後にある FDA の公式な出典をご覧ください。

DECISION DATEMay 14, 2018PRODUCT CODEMUE

Indications for use

Pristina Serena is an optional accessory of Senographe Pristina intended to provide accurate location of lesions in the breast in three dimensions. Indications for Use The Pristina Serena option provides the three-dimensional location of target lesions, using information obtained from stereotactic pairs of two-dimensional X-ray images. This information provides guidance for a variety of minimally invasive or interventional procedures in the GE Healthcare breast such as: vacuum assisted biopsy, core biopsy, pre-surgical localization (e.g. hookwire), and fine needle aspirations (FNA). Device Comparison: Pristina Serena uses the same fundamental technology as Senographe Stereo in terms of lesion targeting technique (2D stereotactic biopsy), stereotactic angle, needle approach (vertical or lateral), field of view and attainable breast volume. Like its predicate, Pristina Serena supports various breast biopsy and intervention devices. The targeting accuracy of Pristina Serena is equivalent to that of Senographe Stereo. The main differences between Pristina Serena and Senographe Stereo include:

- Ability to target a lesion above the compression paddle in vertical approach;

- Ability to switch needle approach without patient repositioning;

- A tilted needle axis to accommodate future 3D biopsy application. Pristina Serena uses the image chain of the Senographe Pristina mammography platform, therefore delivering images of quality equivalent to that of standard screening/diagnostic images.

Performance Testing The safety and performance of the Pristina Serena option was demonstrated through engineering bench performance testing such as:

• Biopsy accuracy testing: verification of the geometrical accuracy between the target lesion identified on the X-ray Stereo pair images and the actual position of the biopsy needle tip (or needle notch).

• Image quality and dose performance testing to confirm that performance in Biopsy mode with Pristina Serena is substantially equivalent to that of Senographe Pristina screening/diagnostic imaging system. In addition, the device has successfully completed required design control testing per GE Healthcare’s quality management system. No unexpected test results were obtained. The Pristina Serena option was designed and will be manufactured under the Quality System Regulations of 21CFR 820 and ISO 13485. The following quality assurance measures were applied to the development of the system:

• Risk Analysis

• Design Reviews GE Healthcare

• Software Development Lifecycle

• Testing on unit level (Module verification)

• Integration testing (System verification)

• Performance testing (Verification)

• Safety testing (Verification)

• Simulated use testing (Validation) These tests were performed to provide the requisite data to substantiate performance, claims, and ultimately substantial equivalence. Testing demonstrated that Pristina Serena performs according to specifications and functions as intended.

See the full product information製品情報をすべて見るには

Device description, AI/software, PCCP, evaluation and limitations are available with an account: seven days of full access after free registration, then with the paid plan.機器の説明、AI・ソフトウェア、PCCP、評価、制限事項は、アカウントでご覧いただけます。無料登録から 7 日間はすべて利用でき、その後は有料プランでご利用いただけます。

Start free 7-day access7日間無料で利用するLog inログイン

OFFICIAL FDA SOURCES

FDA Record and Public Document Status

Record and document link states are stored separately.FDA Record と公開文書のリンクの状態は、別々に記録しています。

Information reviewed:情報の確認日: August 27, 2026